Conservation of C4BP-binding Sequence Patterns in Streptococcus pyogenes M and Enn Proteins.

C4BP Cross-reactivity Immunogen M protein Streptococcus pyogenes

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
13 Jun 2024
Historique:
received: 23 04 2024
revised: 03 06 2024
accepted: 11 06 2024
medline: 16 6 2024
pubmed: 16 6 2024
entrez: 15 6 2024
Statut: aheadofprint

Résumé

Antigenically sequence variable M proteins of the major bacterial pathogen Streptococcus pyogenes (Strep A) are responsible for recruiting human C4b-binding protein (C4BP) to the bacterial surface, which enables Strep A to evade destruction by the immune system. The most sequence divergent portion of M proteins, the hypervariable region (HVR), is responsible for binding C4BP. Structural evidence points to the conservation of two C4BP-binding sequence patterns (M2 and M22) in the HVR of numerous M proteins, with this conservation applicable to vaccine immunogen design. These two patterns, however, only partially explain C4BP-binding by Strep A. Here, we identified several M proteins that lack these patterns but still bind C4BP, and determined the structures of two, M68 and M87 HVRs, in complex with a C4BP fragment. Mutagenesis of these M proteins led to identification of amino acids that are crucial for C4BP-binding, enabling formulation of new C4BP-binding patterns. Mutagenesis was also carried out on M2 and M22 proteins to refine or generate experimentally grounded C4BP-binding patterns. The M22 pattern was the most prevalent among M proteins, followed by the M87 and M2 patterns, while the M68 pattern was rare. These patterns, except for M68, were also evident in numerous M-like Enn proteins. Binding of C4BP via these patterns to Enn proteins was verified. We conclude that C4BP-binding patterns occur frequently in Strep A strains of differing M types, being present in their M or Enn proteins, or frequently both, providing further impetus for their use as vaccine immunogens.

Identifiants

pubmed: 38879009
pii: S0021-9258(24)01979-3
doi: 10.1016/j.jbc.2024.107478
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107478

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Piotr Kolesiński (P)

Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093 USA.

Matthew McGowan (M)

Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093 USA.

Anne Botteaux (A)

Molecular Bacteriology Laboratory, European Plotkin Institute for Vaccinology, ULB, Brussels, Belgium.

Pierre R Smeesters (PR)

Molecular Bacteriology Laboratory, European Plotkin Institute for Vaccinology, ULB, Brussels, Belgium; Department of Paediatrics, Brussels University Hospital, Academic Children Hospital Queen Fabiola, Université libre de Bruxelles, Brussels, Belgium.

Partho Ghosh (P)

Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093 USA. Electronic address: pghosh@ucsd.edu.

Classifications MeSH